Nav: Home

Study shows new treatment strategy in head & neck cancer not better than current standard

December 08, 2016

(TORONTO, Canada - Dec. 8, 2016) - Results of the largest Canadian clinical trial to date comparing standard treatment for locally advanced squamous cell head and neck cancer with an experimental treatment did not show the new treatment is superior.

The findings, published online today in JAMA Oncology, mean that for now the standard of care for these patients remains combined chemotherapy and radiotherapy. (DOI: 10.1001/jamaoncol.2016.4510)

Nevertheless, the research provides invaluable clinical and quality of life data, including biospecimens from 320 patients, to inform future studies, say co-principal investigators Drs. Lillian Siu and John Waldron at the Princess Margaret Cancer Centre, University Health Network.

Dr. Siu, medical oncologist and Professor of Medicine, and Dr. Waldron, radiation oncologist and Associate Professor of Radiation Oncology, both at University of Toronto, talk about the study, at https://youtu.be/yoWWfZZBzKw. The study was sponsored and conducted by the Canadian Cancer Trials Group, whose core funder is the Canadian Cancer Society.

Seventeen Canadian cancer centres participated in the Phase III randomized clinical trial from December 2008 to November 2011 that analyzed progression-free survival as its primary end point. Half the patients received the current standard of care; the other half received the new treatment - a targeted, biological agent that inhibits cancer growth, plus accelerated radiation ("bioradiotherapy"). In the end, there was no statistically significant difference between the two treatment arms.

Dr. Waldron says: "Our intention was to look at the effect of this new class of compounds. We used the drug panitumumab which is a member of a specific class of drug known as EGFR inhibitors. In a previous randomized study, combination of a different EGFR inhibitor with radiotherapy compared to radiotherapy alone has been shown to improve outcomes.

"So we thought if traditional treatment is radiation and cytotoxic chemotherapy (cisplatin), can we change the standard of care by dropping cisplatin and adding in the new agent, which may have fewer side effects and can be used with a wider range of patients."

When the study was designed, less was known about the role of the human papilloma virus (HPV) in driving the increasing incidence of head and neck cancer. Now it is known that HPV-positive patients can respond better to treatment and so the researchers are retrospectively analyzing the biospecimens from the study to add to the growing canon of HPV knowledge.

For the researchers, the potential use of bioradiotherapy as a new treatment strategy is far from determined. Says Dr. Siu: "A larger study of 900+ participants has been completed by another group in the U.S. and we anticipate those results in the near future to help us understand whether bioradiotherapy can replace the current standard of care for patients with locally advanced head and neck cancer."

Drs. Siu and Waldron say that their study offered a valuable opportunity to standardize specialized radiation techniques which were delivered with extremely high levels of quality across the participating sites and now represent the standard of care for head and neck cancer patients.

They conclude: "It also provided a platform for detailed assessment of quality of life, swallowing symptoms and physiologic swallowing function for these patients, which will be an invaluable source of data to characterize the impact of disease and treatment from the patient perspective."

Dr. Waldron adds: "One of the main benefits of the study was to rally the Canadian head and neck oncology community in terms of support. It was the first Canadian Cancer Trials Group led randomized study of head and neck cancer and it provided patients with consistent, standardized care."

The ability to test new therapies in tumours such as head and neck cancer requires collaboration between patients and health care providers, says Dr. Wendy Parulekar, Senior Investigator who supervised this study at Queen's University. 'This study represents a major accomplishment for the Canadian research community and we are committed to building on this success."
-end-
The research was funded by Amgen Inc., the Canadian Cancer Society Research Institute, and The Princess Margaret Cancer Foundation.

About Princess Margaret Cancer Centre, University Health Network

The Princess Margaret Cancer Centre has achieved an international reputation as a global leader in the fight against cancer and delivering personalized cancer medicine. The Princess Margaret, one of the top five international cancer research centres, is a member of the University Health Network, which also includes Toronto General Hospital, Toronto Western Hospital, Toronto Rehabilitation Institute and the Michener Institute for Education; all affiliated with the University of Toronto. For more information, go to http://www.theprincessmargaret.ca or http://www.uhn.ca .

Media contact: Jane Finlayson, Public Affairs, (416) 946-2846 jane.finlayson@uhn.ca

About the Canadian Cancer Trials Group (CCTG)

The CCTG is the only Canadian cooperative cancer trials group conducting the entire range of cancer trials from early phase studies to large international randomized controlled trials across all cancer types. Its primary mission is to assess the effectiveness of interventions to prevent the development of cancer or improve the care of those patients who do develop cancer. It is a national research program of the Canadian Cancer Society. Its Central Operations and Statistics Centre is located at Queen's University in Kingston, Ontario, Canada. For more information on CCTG, please visit https://www.ctg.queensu.ca/.

University Health Network

Related Radiotherapy Articles:

Oxygen in hyperbaric chamber provides relief after radiotherapy
Hyperbaric oxygen therapy (HBOT) can relieve self-reported symptoms and side-effects of radiotherapy against cancer in the pelvic region, a study shows.
Men can be spared radiotherapy after surgery
Men with prostate cancer can be spared radiotherapy after surgery, according to late breaking results from a study led by The Royal Marsden NHS Foundation Trust.
Men with prostate cancer can be spared radiotherapy after surgery
Men with prostate cancer can be spared radiotherapy after surgery, according to late breaking results of the RADICALS-RT trial presented at the ESMO Congress 2019 in Barcelona, Spain.
Radiotherapy targets tumours precisely -- with less damage to healthy cells
A new way of concentrating radiotherapy dose in tumours, while minimising damage to healthy cells, has been proposed in research led by scientists at the University of Strathclyde.
Hurricane disasters associated with poorer outcomes for radiotherapy patients
Lung cancer patients who had a hurricane disaster declared during radiotherapy had worse overall survival than those who completed treatment in normal circumstances.
Women in developing countries need radiotherapy and vaccines for cervical cancer
Millions of women in low- and middle-income countries will need life-saving radiotherapy to treat their cervical cancer, despite the growth of essential human papilloma virus (HPV) vaccination prevention programs.
Radiotherapy doubles survival for patients with mesothelioma
Mesothelioma patients are twice as likely to survive for two years or longer, if they are treated with a high dose of radiation to the affected side of the trunk, according to research presented at the ESTRO 38 conference.
Using 3D models to reduce side effects of radiotherapy
The debilitating side effects of radiotherapy could soon be a thing of the past thanks to a breakthrough by University of South Australia (UniSA) and Harvard University researchers.
Radiotherapy is 'undervalued' and 'needs greater investment' say experts
Radiotherapy is 'undervalued' and 'needs greater investment' according to a new report published today commissioned by the Marie Curie Legacy Campaign -- an initiative of the European Society for Radiotherapy and Oncology (ESTRO) and the ESTRO Cancer Foundation (ECF).
Concurrent chemo-radiotherapy should be a treatment option for elderly patients with LS-S
Elderly patients with limited-stage small cell lung cancer (LS-SCLC) showed similar survival and toxicity compared to their younger counterparts when treated with concurrent chemo-radiotherapy.
More Radiotherapy News and Radiotherapy Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.